RU2482877C2 - Композиции и способы для лечения опухоли - Google Patents

Композиции и способы для лечения опухоли Download PDF

Info

Publication number
RU2482877C2
RU2482877C2 RU2009126588/15A RU2009126588A RU2482877C2 RU 2482877 C2 RU2482877 C2 RU 2482877C2 RU 2009126588/15 A RU2009126588/15 A RU 2009126588/15A RU 2009126588 A RU2009126588 A RU 2009126588A RU 2482877 C2 RU2482877 C2 RU 2482877C2
Authority
RU
Russia
Prior art keywords
thalidomide
melphalan
antibody
bortezomib
patient
Prior art date
Application number
RU2009126588/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2009126588A (ru
Inventor
Роберт Д. МАСС
Грегори Д. ПЛАУМАН
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2009126588A publication Critical patent/RU2009126588A/ru
Application granted granted Critical
Publication of RU2482877C2 publication Critical patent/RU2482877C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2009126588/15A 2006-12-11 2007-05-04 Композиции и способы для лечения опухоли RU2482877C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
US60/874,460 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (2)

Publication Number Publication Date
RU2009126588A RU2009126588A (ru) 2011-01-20
RU2482877C2 true RU2482877C2 (ru) 2013-05-27

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009126588/15A RU2482877C2 (ru) 2006-12-11 2007-05-04 Композиции и способы для лечения опухоли

Country Status (17)

Country Link
US (1) US20100086544A1 (https=)
EP (1) EP2099489B1 (https=)
JP (1) JP2010512407A (https=)
KR (1) KR101320198B1 (https=)
CN (1) CN101547705B (https=)
AU (1) AU2007333565A1 (https=)
BR (1) BRPI0717688A2 (https=)
CA (1) CA2670707A1 (https=)
DK (1) DK2099489T3 (https=)
IL (1) IL198852A (https=)
MX (1) MX2009006202A (https=)
NZ (1) NZ577058A (https=)
RU (1) RU2482877C2 (https=)
SG (1) SG177891A1 (https=)
SI (1) SI2099489T1 (https=)
WO (1) WO2008073509A2 (https=)
ZA (1) ZA200903489B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2836995C1 (ru) * 2024-04-18 2025-03-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения пациентов с множественной миеломой, осложненной двойной рефрактерностью, с помощью адоптивной иммунотерапии на основе натуральных киллеров

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012088438A1 (en) * 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
MX356102B (es) * 2012-03-14 2018-05-14 Univ Indiana Res & Tech Corp Compuestos y métodos para tratar leucemia.
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
FI3328843T3 (fi) 2015-07-27 2023-01-31 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
ES2774510T3 (es) 2015-07-27 2020-07-21 Chong Kun Dang Pharmaceutical Corp Derivados de 1,3,4-oxadiazol sulfamida como inhibidores de histona desacetilasa 6 y composición farmacéutica que comprende los mismos
DK3330259T3 (da) 2015-07-27 2020-08-10 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
RU2709207C2 (ru) 2015-08-04 2019-12-17 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
HRP20230201T1 (hr) 2015-10-12 2023-03-31 Chong Kun Dang Pharmaceutical Corp. Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
AU2020284606B2 (en) 2019-05-31 2023-01-19 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197477C2 (ru) * 1997-12-05 2003-01-27 АСТРАЗЕНЕКА Ю Кей ЛИМИТЕД Производные адамантана, способ их получения, фармацевтическая композиция на их основе, способ ее получения и способ воздействия на иммуносупрессию
WO2004103274A2 (en) * 2003-05-15 2004-12-02 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
PT1115704E (pt) * 1998-09-25 2003-11-28 Boehringer Ingelheim Pharma Novas indolinonas substituidas com accao inibidora sobre varias quinases e complexos ciclina/cdk
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197477C2 (ru) * 1997-12-05 2003-01-27 АСТРАЗЕНЕКА Ю Кей ЛИМИТЕД Производные адамантана, способ их получения, фармацевтическая композиция на их основе, способ ее получения и способ воздействия на иммуносупрессию
WO2004103274A2 (en) * 2003-05-15 2004-12-02 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERENSON JR et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma // J Clin Oncol. 2006 Feb 20; 24(6):937-44. *
HERBST RS et al. Phase I/II trial evaluating the anti-vascular endothclial growth factor monoclonal antibody bevacizumab in combination with the HER-l/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer //J Clin Oncol. 2005 Apr 10; 23(11):2544-55. *
HIDESHIMA T et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells // Oncogene. 2004 Nov 18; 23(54): 8766-76. *
HIDESHIMA T et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells // Oncogene. 2004 Nov 18; 23(54): 8766-76. HERBST RS et al. Phase I/II trial evaluating the anti-vascular endothclial growth factor monoclonal antibody bevacizumab in combination with the HER-l/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer //J Clin Oncol. 2005 Apr 10; 23(11):2544-55. BERENSON JR et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma // J Clin Oncol. 2006 Feb 20; 24(6):937-44. ZANGARI M et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma // Clin Cancer Res. 2004 Jan 1; 10 (1 Pt 1):88-95. *
ZANGARI M et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma // Clin Cancer Res. 2004 Jan 1; 10 (1 Pt 1):88-95. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2836995C1 (ru) * 2024-04-18 2025-03-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения пациентов с множественной миеломой, осложненной двойной рефрактерностью, с помощью адоптивной иммунотерапии на основе натуральных киллеров

Also Published As

Publication number Publication date
CA2670707A1 (en) 2008-06-19
US20100086544A1 (en) 2010-04-08
IL198852A0 (en) 2011-08-01
EP2099489B1 (en) 2014-05-21
RU2009126588A (ru) 2011-01-20
WO2008073509A3 (en) 2009-01-08
EP2099489A2 (en) 2009-09-16
DK2099489T3 (da) 2014-08-18
CN101547705B (zh) 2013-06-12
HK1131064A1 (en) 2010-01-15
SG177891A1 (en) 2012-02-28
CN101547705A (zh) 2009-09-30
AU2007333565A1 (en) 2008-06-19
IL198852A (en) 2013-06-27
JP2010512407A (ja) 2010-04-22
MX2009006202A (es) 2009-06-22
NZ577058A (en) 2012-04-27
WO2008073509A2 (en) 2008-06-19
KR101320198B1 (ko) 2013-10-30
BRPI0717688A2 (pt) 2013-01-22
SI2099489T1 (sl) 2014-09-30
KR20090087908A (ko) 2009-08-18
ZA200903489B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
RU2482877C2 (ru) Композиции и способы для лечения опухоли
JP2023039448A (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
JP2020114840A (ja) がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤
EP3677278B1 (en) Isoform selective tgfbeta1 inhibitors and use thereof
CN111247172A (zh) 基于抗cd47剂的卵巢癌疗法
CN112203695A (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
EP2849784A1 (en) Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
CA2849746A1 (en) Anti-icam-1 antibodies to treat multiple-myeloma related disorders
EP2849783A1 (en) Combination of cd37 antibodies with further agents
WO2018067819A1 (en) Compositions and methods for treatment of cancers
JP2024041982A (ja) 胃癌の検出および治療のための組成物および方法
EP4489789A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
CA3032542A1 (en) Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
BR112021004935A2 (pt) combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer
CN112638392A (zh) 组合疗法
CA3213216A1 (en) Tgf-beta inhibitors and use thereof
JP2026504943A (ja) 併用療法のための方法および組成物
AU2018203727A1 (en) Compositions and methods for treating a neoplasm
AU2014201911A1 (en) Compositions and methods for treating a neoplasm
HK1131064B (en) Compositions and methods for treating a neoplasm
US20160106837A1 (en) Combination of cd37 antibodies with chlorambucil
US20240294623A1 (en) Tgf-beta inhibitors and therapeutic use thereof
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
HK40029255A (en) Anti-cd47 agent-based ovarian cancer therapy
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200505